Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan Co.
Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of Japan-based MicroBiopharm Japan Co. (MBJ) for approximately Rs 1,300 crore through its wholly owned subsidiary, Themis Biosyn Japan Limited. The acquisition, funded by a mix of equity and debt arranged by Avendus Capital, provides GTBL access to MBJ's three GMP-compliant manufacturing plants, over 60 years of pharmaceutical expertise, and established global client relationships. This move supports GTBL's strategy to expand as a global contract development and manufacturing organization (CDMO), enhancing its capabilities in fermentation and biologics.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 42/100.
Outlets measured: moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 18 Sept, 10:37 am. Other outlets followed.